Silver
Advancements in ourunderstanding of genetics have the potential to change the practice of medicineand enable genomics-based healthcare. With streamlined workflows and advanced informatics, Illumina sequencing and array technologies and analysis services are allowing you to explore the genome more than everbefore. Together, we can address healthcare in ways never before imagined.Visit the Illumina booth to find out how.
TruSightTM Oncolgy 500 is an NGS assay analyzing 523 cancer-relevant genes from DNA and RNA derived from FFPE tissue in one integrated workflow. It accesses multiple variant types in a single assay i.e. SNVs, Indels, fusion, splice variants, and emerging immunotherapy biomarkers including TMB and MSI. It is currently in the track of CE-IVD and USFDA IVD and circulatory tumor DNA (liquid biopsy) test is under development.